|
|
Article: CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
- Article from:
- Worldwide Biotech
- Article date:
- May 1, 2005
CopyrightCOPYRIGHT 2005 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) has announced that allied contract manufacturer DSM Biologics has signed a PER.C6 research license agreement with the Japanese pharmaceutical company Mitsubishi Pharma Corporation. This license agreement allows Mitsubishi to use the PER.C6 cell line for production of certain recombinant therapeutic proteins. This license agreement is the second license agreement signed by DSM Biologics with a Japanese company recently.
Under the terms of the agreement, Mitsubishi will make an upfront payment and pay annual maintenance fees. Further financial details were not disclosed.
About CrucellP ...